From Health Canada:
At Health Canada’s request, Novartis Pharmaceuticals Canada Inc. is suspending marketing and sales of Zelnorm* (tegaserod hydrogen maleate) tablets in Canada to permit further evaluation of important safety information.
For health care professionals
For the public
Sunday, April 08, 2007
Voluntary suspension of sales of Zelnorm due to cardiovascular ischemic events
Labels:
Health Canada warning,
IBS,
tegaserod,
Zelnorm
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment